Microbial-based Cancer Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed)

Microbial-based Cancer Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) is sponsored by National Institutes of Health (NIH). This R21 grant encourages exploratory research on microbial-based cancer therapies, including the investigation of microbial ecology and host-pathogen interactions in cancer contexts.

A **. gov** website belongs to an official government organization in the United States.

* How to Apply for Grants * **Applicant Resources** * Adobe Software Compatibility * Submitting UTF-8 Special Characters * Encountering Error Messages * Grantor Standard Language * Submitting UTF-8 Special Characters * **Applicant System-To-System** * Reference Implementation * **Grantor System-To-System** * Reference Implementation * SF-424 Individual Family * SF-424 Mandatory Family * SF-424 Short Organization Family * Post-Award Reporting Forms * Country and State Lists Updates * **Manage Subscriptions** * Program Management Office * Grants.

gov Maintenance Calendar Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) Department of Health and Human Services National Institutes of Health Document Type:Grants Notice Funding Opportunity Number:PAR-25-108 Funding Opportunity Title:Microbial-based Cancer Imaging and Therapy - Bugs as Drugs (R21 Clinical Trial Not Allowed) Opportunity Category:Discretionary Opportunity Category Explanation: Funding Instrument Type:Grant Category of Funding Activity:Education Expected Number of Awards: Assistance Listings:93.

121 -- Oral Diseases and Disorders Research 93. 395 -- Cancer Treatment Research 93.

396 -- Cancer Biology Research Cost Sharing or Matching Requirement:No Last Updated Date:Nov 12, 2024 Original Closing Date for Applications:May 07, 2025 Current Closing Date for Applications:May 07, 2025 Archive Date:Jun 12, 2025 Estimated Total Program Funding: Eligible Applicants:Special district governments Native American tribal organizations (other than Federally recognized tribal governments) Others (see text field entitled "Additional Information on Eligibility" for clarification) Public housing authorities/Indian housing authorities Private institutions of higher education Independent school districts Nonprofits that do not have a 501(c)(3) status with the IRS, other than institutions of higher education For profit organizations other than small businesses Native American tribal governments (Federally recognized) City or township governments Public and State controlled institutions of higher education Nonprofits having a 501(c)(3) status with the IRS, other than institutions of higher education Additional Information on Eligibility:Other Eligible Applicants include the following: Alaska Native and Native Hawaiian Serving Institutions; Asian American Native American Pacific Islander Serving Institutions (AANAPISISs); Eligible Agencies of the Federal Government; Faith-based or Community-based Organizations; Hispanic-serving Institutions; Historically Black Colleges and Universities (HBCUs); Indian/Native American Tribal Governments (Other than Federally Recognized); Non-domestic (non-U.S.) Entities (Foreign Organizations); Regional Organizations; Tribally Controlled Colleges and Universities (TCCUs) ; U.S. Territory or Possession.

## Additional Information Agency Name:National Institutes of Health Description:Through this Notice of Funding Opportunity (NOFO), the National Cancer Institute (NCI) solicits grant applications proposing to utilize bacteria, archaebacteria, bacteriophages, or other non-oncolytic viruses and their natural products to study the underlying mechanisms of the complex interactions between microorganisms, tumors, and the immune system, and to explore their clinical potential for cancer imaging, therapeutics or diagnostics.

Projects can focus on using microorganisms as anti-tumor agents, as activators of anti-tumor immunity, or as delivery vehicles for treatment, diagnosis, or imaging, complementing or synergizing with existing tools and approaches. This NOFO will support basic mechanistic and preclinical studies in cell culture and animal models.

Applicants are encouraged to address both the microbial and tumor aspects of microbial tumor interactions relevant to microbial-based cancer therapy (including therapies for oral cancer), tumor imaging, tumor detection, or diagnosis.

The R21 FOA is intended to encourage exploratory projects that are at an early conceptual stage feasibility study (inception through preliminary development) to demonstrate the core functional capabilities of the proposed approach. The proposed projects may involve considerable risk and should be aimed at producing breakthroughs in microbial-based cancer therapy, imaging, or diagnosis.

This funding opportunity is part of broader NCI-sponsored research on microbial-based cancer therapy. Link to Additional Information:https://grants. nih.

gov/grants/guide/pa-files/PAR-25-108. html Grantor Contact Information:If you have difficulty accessing the full announcement electronically, please contact: See Section VII. Agency Contacts within the full opportunity announcement for all other inquires.

#### Health & Human Services * Frequently Asked Questions ## Your session will expire in 3 minutes. To continue working, click on the "OK" button below. This is being done to protect your privacy.

Unsaved changes will be lost.